Astellas Pharma vs. Apsen: Appeal Dismissed in Mirabegron Patent Case in São Paulo
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Astellas Pharma, Inc. v. Apsen Farmacêutica S.A. |
| Numéro de dossier | 2131917-74.2024.8.26.0000 |
| Tribunal | Court of Justice of São Paulo, Brazil |
| Appel rejeté | August 21, 2024 |
| Résultat | Plaintiff Win — Appeal Dismissed |
| Brevets en cause | |
| Produits incriminés | Apsen’s Mirabegron Generic Product (allegedly infringing MYRBETRIC®) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Tokyo-headquartered global pharmaceutical company with a substantial IP portfolio spanning urology, oncology, and transplantation therapeutics. Holder of patent BRPI0213570B1.
🛡️ Défendeur
Well-established Brazilian pharmaceutical company with a strong presence in the domestic generics and branded generics market.
Le brevet en cause
This case centered on **BRPI0213570B1**, a Brazilian patent corresponding to Astellas’s proprietary mirabegron compound technology. Mirabegron operates as a beta-3 adrenergic receptor agonist—a mechanism of action distinct from traditional anticholinergic OAB treatments—and represents a significant therapeutic advance. The patent protects core formulation and/or compound aspects of this technology in Brazil.
- • BRPI0213570B1 — Mirabegron compound technology for overactive bladder
Developing a Mirabegron-based Product?
Check if your pharmaceutical formulation might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The Court of Justice of São Paulo ruled unequivocally: “The claim of the present appeal is denied.” The appeal was dismissed in its entirety, reinforcing Astellas’s IP position in Brazil. No specific damages amount was disclosed, consistent with the appellate procedural posture where the court was reviewing, rather than reassessing, underlying infringement determinations.
Principales questions juridiques
The Court of Justice of São Paulo’s dismissal of the appeal indicates that Apsen failed to persuade the appellate panel that reversible legal or factual errors occurred in the underlying proceedings. Brazilian appellate courts apply a structured review standard—appellants must demonstrate specific grounds for reversal. The clean dismissal here suggests the appellate arguments did not meet this threshold.
While the specific legal reasoning of the panel was not detailed in the provided case data, the outcome is consistent with Brazilian courts’ increasing rigor in evaluating pharmaceutical patent challenges. Brazil’s IP legal framework under Lei No. 9.279/96 (Industrial Property Law) provides robust protection for validly granted patents, and the INPI’s examination process has yielded patents that Brazilian courts have demonstrated willingness to enforce.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in mirabegron development. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige pharmaceutique.
- View all related patents for mirabegron technology
- See which companies are most active in beta-3 agonist IP
- Understand claim construction patterns relevant to pharma
🔍 Vérifier les risques liés à mon produit
Run a comprehensive FTO analysis for your mirabegron formulation or related technology.
- Saisissez les détails de votre formulation ou ses caractéristiques techniques.
- AI identifies potentially blocking patents (e.g., BRPI0213570B1)
- Get actionable risk assessment report for Brazil
Zone à haut risque
Mirabegron Formulations & Derivatives
1 Brevet en cause
BRPI0213570B1
Options de contournement
Available, but challenging for core compounds
✅ Points clés à retenir
Brazilian appellate courts show rigor in pharmaceutical IP disputes, often upholding lower court infringement rulings.
Rechercher la jurisprudence connexe →Appeal strategies in Brazilian IP cases must introduce distinct legal arguments—rearticulation of first-instance positions carries high dismissal risk.
Explorer les précédents →Consider parallel INPI nullity proceedings as an important tactical option for patent challengers operating alongside court litigation.
Learn about INPI proceedings →Foire aux questions
The case involved Brazilian patent BRPI0213570B1, covering mirabegron-related technology, which protects Astellas’s MYRBETRIC® overactive bladder treatment in Brazil.
The Court of Justice of São Paulo denied the appeal in its entirety (Case No. 2131917-74.2024.8.26.0000), concluding on August 21, 2024. The appeal was dismissed without reversal of the underlying infringement action outcome.
The ruling reinforces Brazilian appellate courts’ willingness to uphold pharmaceutical patent enforcement, strengthening originator companies’ litigation posture and raising the strategic bar for generic challengers pursuing appellate remedies.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- Court of Justice of São Paulo (Tribunal de Justiça do Estado de São Paulo) — Case 2131917-74.2024.8.26.0000
- Brazilian National Institute of Industrial Property (INPI) — Patent Database
- Brazilian Industrial Property Law (Lei No. 9.279/96)
- World Intellectual Property Organization (WIPO) — Patent Resources
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.